News

Article

Catalent Finalizes RheinCell Therapeutics Acquisition

Catalent finalizes their acquisition of iPSC developer and manufacturer RheinCell Therapeutics.

On August 4th, 2021, Catalent announced that they had finalized the acquisition of RheinCell Therapeutics, a manufacturer and developer of induced pluripotent stem cells (iPSC) technologies. The company had announced their principal agreement to acquire RheinCell on June 24th, 2021.

Founded in 2017, RheinCell research has broad applicability for cell-based therapies. As a stem cell, iSPCs can be differentiated into various cell types, which means they can be used for a variety of different cell therapies.

According to a company press release, RheinCell’s acquisition grants Catalent full good manufacturing practice (GMP) lines, non-GMP equivalent iPSC banks, and iSPC development and reprogramming. Catalent will now have accelerated access to high-quality iSPC banks and the ability to build on their existing iSPC services, among other things.

Source: Catalent

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Related Content